Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers

Journal of Clinical Pharmacology

Volumn 50, Issue 2, 2010, Pages 205-213

  Skerjanec, Andrej ^a   Jixian Wang, ^a   Maren, Kelly ^a   Rojkjaer, Lisa ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical pharmacology; Clinical trials; Drug information; Drug metabolism; Hematology; Pharmacokinetics

Indexed keywords

1 HYDROXYMIDAZOLAM; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; DEFERASIROX; DRUG METABOLITE; GLUCOSE; MIDAZOLAM; PLACEBO; REPAGLINIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INDUCTION; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; RACE DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ANESTHETICS, INTRAVENOUS; ARYL HYDROCARBON HYDROXYLASES; BENZOIC ACIDS; CARBAMATES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IRON CHELATING AGENTS; MALE; MIDAZOLAM; PIPERIDINES; RIFAMPIN; TRIAZOLES;

EID: 75749153664     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009340418     Document Type: Article

References (21)

1. Nick H., Acklin P., Lattmann R., et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003 ; 10: 1065-1076.
2. Yang LP, Keam SJ, Keating GM Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs. 2007 ; 67: 2211-2230.
3. Porter JB Concepts and goals in the management of transfusional iron overload. Am J Hematol. 2007 ; 82: 1136-1139.
4. Nisbet-Brown E., Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003 ; 361: 1597-1602.
5. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008 ; 9: 2391-2402.
6. Cohen AR, Glimm E., Porter JB Effect of transfusional iron intake on response to chelation therapy in B-thalassemia major. Blood. 2008 ; 111: 583-587.
7. Shashaty G., Frankewich R., Chakraborti T., et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park). 2006 ; 20: 1799-1806, 1811 ; discussion 1811-1813, 1817.
8. Weiss HM, Fresneau M., Camenisch GP, et al. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab Dispos. 2006 ; 34: 971-975.
9. Sechaud R., Robeva A., Belleli R., et al. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol. 2008 ; 48: 919-925.
10. Galanello R. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. Ann N Y Acad Sci. 2005 ; 1054: 183-185.
11. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001 ; 61: 1625-1660.
12. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999 ; 66: 461-471.
13. Prueksaritanont T., Vega JM, Rogers JD, et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol. 2000 ; 40: 1274-1279.
14. Zdravkovic M., Olsen AK, Christiansen T., et al. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur J Clin Pharmacol. 2003 ; 58: 683-688.
15. Ahonen J., Olkkola KT, Neuvonen PJ Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol. 1997 ; 51: 415-419.
16. Niemi M., Backman JT, Neuvonen M., et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther. 2000 ; 68: 495-500. (Pubitemid 30953869)
17. Galanello R., Piga A., Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008 ; 48: 428-435.
18. Martin NE, Howell SR, Martin LL, et al. No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/ neutral endopeptidase inhibitor, M100240. J Clin Pharmacol. 2004 ; 44: 379-387.
19. Kajosaari LI, Jaakkola T., Neuvonen PJ, et al. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol. 2006 ; 62: 217-223.
20. Kajosaari LI, Niemi M., Backman JT, et al. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther. 2006 ; 79: 231-242.
21. Burger DM, Meenhorst PL, Koks CH, et al. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 ; 37: 1426-1431.